At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Closed 09-18 16:00:00 EDT
16.69
-0.03
-0.18%
盘后16.69
+0.000.00%
19:30 EDT
High16.87Low16.53Vol1.15M
Open16.70D1 Closing16.72Amplitude2.06%
Mkt Cap1.94BTradable Cap1.61BTotal Shares116.45M
T/O19.24MT/O Rate1.20%Tradable Shares96.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novocure Director Timothy Scannell Retires from Board
Reuters  ·  09-09
Novocure Director Timothy Scannell Retires from Board
NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors
TIPRANKS  ·  09-05
NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors
Novocure CEO to Speak at Wells Fargo Healthcare Conference
Reuters  ·  09-02
Novocure CEO to Speak at Wells Fargo Healthcare Conference
Novocure Announces Upcoming Investor Events
THOMSON REUTERS  ·  09-02
Novocure Announces Upcoming Investor Events
Oncology Firm Novocure Says Cyberattack Exposed US Patient Records
Reuters  ·  09-01
Oncology Firm Novocure Says Cyberattack Exposed US Patient Records
Novocure aware of unauthorized access to some information systems
TIPRANKS  ·  09-01
Novocure aware of unauthorized access to some information systems
Novocure Limited: Do not Believe Incident Will Have Material Impact or Likely Material Impact on Financial Condition & Results of Operations
THOMSON REUTERS  ·  09-01
Novocure Limited: Do not Believe Incident Will Have Material Impact or Likely Material Impact on Financial Condition & Results of Operations
Novocure - no Access to Medical Devices Obtained; Operations and Systems Fully Functional - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - no Access to Medical Devices Obtained; Operations and Systems Fully Functional - SEC Filing
Novocure - Reports Unauthorized Access to Information Systems in Mid-August 2026 - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - Reports Unauthorized Access to Information Systems in Mid-August 2026 - SEC Filing
Novocure - Exposed Data Included Internal Patient ID Numbers for over 1,400 U.S. Records - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - Exposed Data Included Internal Patient ID Numbers for over 1,400 U.S. Records - SEC Filing
Novocure - General Contact Information for Providers and Employees was Exposed - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - General Contact Information for Providers and Employees was Exposed - SEC Filing
Novocure Investigates Unauthorized Access to Some Information Systems
Reuters  ·  09-01
Novocure Investigates Unauthorized Access to Some Information Systems
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?
Simply Wall St.  ·  08-30
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?
Simply Wall St.  ·  08-22
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued
Simply Wall St.  ·  08-11
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years
Simply Wall St.  ·  07-30
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
Benzinga Earnings  ·  07-24
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating
MT Newswires Live  ·  07-24
Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating
Novocure price target raised to $20 from $18 at Wedbush
TIPRANKS  ·  07-24
Novocure price target raised to $20 from $18 at Wedbush
NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery
TradingKey  ·  07-24
NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery

Introduction

Company Name.
NovoCure
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Issue price:
--